Report cover image

Insulin Market by Drug (Biologic, Biosimilar), Type (Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin), Application - Global Forecast 2023-2030

Publisher 360iResearch
Published Oct 05, 2023
Length 196 Pages
SKU # IRE18312795

Description

Insulin Market by Drug (Biologic, Biosimilar), Type (Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin), Application - Global Forecast 2023-2030


The Insulin Market is projected to reach USD 73.03 billion by 2030 from USD 40.76 billion in 2022, at a CAGR of 7.56% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Insulin Market.
  • Based on Drug, market is studied across Biologic and Biosimilar. The Biosimilar commanded largest market share of 65.54% in 2022, followed by Biologic.
  • Based on Type, market is studied across Intermediate-acting Insulin, Long-acting Insulin, Premixed Insulin, Rapid-acting Insulin, and Short-acting Insulin. The Long-acting Insulin commanded largest market share of 34.54% in 2022, followed by Intermediate-acting Insulin.
  • Based on Application, market is studied across Type I Diabetes and Type II Diabetes. The Type I Diabetes commanded largest market share of 71.46% in 2022, followed by Type II Diabetes.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 43.09% in 2022, followed by Americas.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Insulin Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Insulin Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Insulin Market, highlighting leading vendors and their innovative profiles. These include ADOCIA, AstraZeneca PLC, Baxter International, Inc., Biocon Limited, Bioton S.A., CardioVends, Eli Lilly and Company, Eva Pharma, GeneSys Biologics, Glenmark Pharmaceuticals Ltd., Gulf Pharmaceutical Industries (Julphar), MannKind Corporation, Merck & Co., Inc., MJ Biopharm Pvt. Ltd., Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., Sanofi Group, Tonghua Dongbao Pharmaceutical Co., Ltd., Viatris Inc., Wockhardt Limited, and Zealand Pharma A/S.

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Insulin Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Insulin Market?
  3. What is the competitive strategic window for identifying opportunities in the Insulin Market?
  4. What are the latest technology trends and regulatory frameworks in the Insulin Market?
  5. What is the market share of the leading vendors in the Insulin Market?
  6. Which modes and strategic moves are suitable for entering the Insulin Market?


Please Note: PDF & Excel + Online Access - 1 Year

Table of Contents

196 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Insulin Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of diabetes and obesity with increasing geriatric population
5.1.1.2. Rapid development in insulin delivery systems
5.1.1.3. Favorable reimbursement policies for insulin products in developed countries
5.1.2. Restraints
5.1.2.1. High cost associated with insulin drugs
5.1.3. Opportunities
5.1.3.1. Potential investments in R&D activities for insulin development
5.1.3.2. Rising approvals for interchangeable biosimilar insulin products
5.1.4. Challenges
5.1.4.1. Complex regulatory landscape and problems related to patient adherence to treatment regimens
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.3.1. Established healthcare infrastructure and development of affordable product have supplemented market growth across the Americas
5.3.2. Government support to increase accessibility and usage of insulin in APAC region
5.3.3. Research & development activities and availability of reimbursement policies for insulin in the EMEA region
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Insulin Market, by Drug
6.1. Introduction
6.2. Biologic
6.3. Biosimilar
7. Insulin Market, by Type
7.1. Introduction
7.2. Intermediate-acting Insulin
7.3. Long-acting Insulin
7.4. Premixed Insulin
7.5. Rapid-acting Insulin
7.6. Short-acting Insulin
8. Insulin Market, by Application
8.1. Introduction
8.2. Type I Diabetes
8.3. Type II Diabetes
9. Americas Insulin Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Insulin Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Insulin Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Agreement, Collaboration, & Partnership
12.3.1.1. Gulf Pharmaceutical Industries 'Julphar' Signs Landmark Agreement with Sunshine Lake Pharma to Pioneer Insulin Biosimilar Manufacturing in MENA
12.3.1.2. California, Drugmaker Partner to Produce Affordable Insulin
12.3.1.3. ADOCIA Announces the Successful Phase 1 Study for BioChaperone Lispro with Partner Tonghua Dongbao
12.3.1.4. Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa
12.3.1.5. Optum, Sanofi Partner on Low Cost Insulin for the Uninsured
12.3.2. New Product Launch & Enhancement
12.3.2.1. Sanofi Launches New Long-Acting Insulin Drug in India
12.3.2.2. Novo Nordisk to Launch Once-a-Week Insulin Regime for Indian Patients
12.3.2.3. Glenmark Launches Type 2 Diabetes and High Insulin Resistance Drug in India; Shares Jump
12.3.2.4. Novo Nordisk Launches Unbranded Biologic of Tresiba Analog Insulin to Expand Affordability Options for Patients
12.3.3. Investment & Funding
12.3.3.1. Insulin Maker GeneSys to Invest USD 50-60 MN to Set Up Plant in Hyderabad
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. ADOCIA
13.1.2. AstraZeneca PLC
13.1.3. Baxter International, Inc.
13.1.4. Biocon Limited
13.1.5. Bioton S.A.
13.1.6. CardioVends
13.1.7. Eli Lilly and Company
13.1.8. Eva Pharma
13.1.9. GeneSys Biologics
13.1.10. Glenmark Pharmaceuticals Ltd.
13.1.11. Gulf Pharmaceutical Industries (Julphar)
13.1.12. MannKind Corporation
13.1.13. Merck & Co., Inc.
13.1.14. MJ Biopharm Pvt. Ltd.
13.1.15. Novartis AG
13.1.16. Novo Nordisk A/S
13.1.17. Oramed Pharmaceuticals Inc.
13.1.18. Pfizer Inc.
13.1.19. Sanofi Group
13.1.20. Tonghua Dongbao Pharmaceutical Co., Ltd.
13.1.21. Viatris Inc.
13.1.22. Wockhardt Limited
13.1.23. Zealand Pharma A/S
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us